search
Back to results

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PS433540
placebo
PS433540
Sponsored by
Ligand Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring hypertension, high blood pressure

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females 30 - 80 years
  • Mean seated Systolic Blood Pressure (SBP) ≥ 150 - ≤ 179 mmHg and mean seated DBP < 110 mmHg at two consecutive qualifying visits. The mean difference in SBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
  • Mean daytime (8AM - 4PM) ambulatory SBP must be between ≥ 140 - ≤ 179 mmHg and mean daytime (8AM - 4PM) Diastolic Blood Pressure (DBP) ≤ 110 mmHg
  • Subjects must have a usual daytime schedule. Night shift workers are excluded from participation.
  • Women of child-bearing potential (WOCBP) and male subjects must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year)

Exclusion Criteria:

  • Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular, renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic/oncologic (including an active malignancy other than basal cell carcinoma), neurologic and psychiatric diseases.
  • Subjects with a history of myocardial infarction, angina, coronary angioplasty, bypass surgery or New York Heart Association (NYHA) class II-IV heart failure within the last 6 months.
  • Subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year.
  • Subjects with diabetes mellitus (type I and type II).

Sites / Locations

  • Premiere Pharmaceutical Research, LLC
  • Clinical Trials Research
  • Long Beach Center for Clinical Research
  • National Research Institute
  • Sacramento Research Medical Group
  • Orange County Research Center
  • Westlake Medical Center
  • University Clinical Research Deland, LLC
  • Alan Graff, MD PA
  • Cedar Crosse Research Center
  • Orland Primary Care Specialists
  • MD Medical Research
  • Lindner Clinical Trial Center
  • Punzi Medical Center
  • Gemini Scientific

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

1

2

3

Arm Description

Matching Placebo

Outcomes

Primary Outcome Measures

Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure

Secondary Outcome Measures

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure
Change From Baseline in Mean Seated Systolic and Diastolic Blood Pressure

Full Information

First Posted
August 29, 2007
Last Updated
September 13, 2011
Sponsor
Ligand Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00522925
Brief Title
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
Official Title
Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ligand Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
hypertension, high blood pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
280 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Matching Placebo
Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
PS433540
Intervention Description
200mg capsule, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo capsule, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
PS433540
Intervention Description
500mg capsule, once daily for 28 days
Primary Outcome Measure Information:
Title
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure
Time Frame
4 weeks of treatment with PS43540
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure
Time Frame
4 weeks of treatment with PS43540
Title
Change From Baseline in Mean Seated Systolic and Diastolic Blood Pressure
Time Frame
4 weeks of treatment with PS43540

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females 30 - 80 years Mean seated Systolic Blood Pressure (SBP) ≥ 150 - ≤ 179 mmHg and mean seated DBP < 110 mmHg at two consecutive qualifying visits. The mean difference in SBP between the two consecutive qualifying visits must be ≤ 10 mmHg. Mean daytime (8AM - 4PM) ambulatory SBP must be between ≥ 140 - ≤ 179 mmHg and mean daytime (8AM - 4PM) Diastolic Blood Pressure (DBP) ≤ 110 mmHg Subjects must have a usual daytime schedule. Night shift workers are excluded from participation. Women of child-bearing potential (WOCBP) and male subjects must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year) Exclusion Criteria: Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular, renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic/oncologic (including an active malignancy other than basal cell carcinoma), neurologic and psychiatric diseases. Subjects with a history of myocardial infarction, angina, coronary angioplasty, bypass surgery or New York Heart Association (NYHA) class II-IV heart failure within the last 6 months. Subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year. Subjects with diabetes mellitus (type I and type II).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joel M Neutel, MD
Organizational Affiliation
Integrium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Premiere Pharmaceutical Research, LLC
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85282
Country
United States
Facility Name
Clinical Trials Research
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Long Beach Center for Clinical Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Sacramento Research Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Orange County Research Center
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Westlake Medical Center
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
University Clinical Research Deland, LLC
City
Deland
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Alan Graff, MD PA
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Facility Name
Cedar Crosse Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Orland Primary Care Specialists
City
Orland Park
State/Province
Illinois
ZIP/Postal Code
60467
Country
United States
Facility Name
MD Medical Research
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Facility Name
Lindner Clinical Trial Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Punzi Medical Center
City
Carrolton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
Gemini Scientific
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53719
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

We'll reach out to this number within 24 hrs